Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin 2: a review.

J E Kolitz, K Welte, K W Sykora

    Arzneimittel-Forschung
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Interleukin 2 (IL 2) is crucial for immune cell function and shows anti-tumor potential. Defects in IL 2 are linked to immunodeficiency, and its role in cancer treatment is under exploration.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Correction: Generation and characterization of a novel hematopoietic progenitor cell line with DC differentiation potential.

    Leukemia·2021
    Same author

    Correction: Generation and characterization of a novel hematopoietic progenitor cell line with DC differentiation potential.

    Leukemia·2021
    Same author

    Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.

    Pediatric blood & cancer·2018
    Same author

    No evidence for microsatellite instability in acute myeloid leukemia.

    Leukemia·2017
    Same author

    The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.

    Leukemia·2017
    Same author

    Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.

    Leukemia·2016
    Same journal

    Wirksamkeit und Verträglichkeit eines pflanzlichen Arzneimittels mit Kapuzinerkressenkraut und Meerrettich bei akuter Sinusitis, akuter Bronchitis und akuter Blasenentzündung im Vergleich zu anderen Therapien unter den Bedingungen der täglichen Praxis.

    Arzneimittel-Forschung·2013
    Same journal

    Abstracts of the Paul-Martini-Stiftung Symposium 2012 in combination with the National Academy of Leopoldina. November 16-17, 2012. Berlin, Germany.

    Arzneimittel-Forschung·2013
    Same journal

    Leave-one-out procedure in the validation of elimination rate constant analysis.

    Arzneimittel-Forschung·2012
    Same journal

    Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.

    Arzneimittel-Forschung·2012
    Same journal

    Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer.

    Arzneimittel-Forschung·2012
    Same journal

    Effect of zeolite nano-materials and artichoke (Cynara scolymus L.) leaf extract on increase in urinary clearance of systematically absorbed nicotine.

    Arzneimittel-Forschung·2012
    See all related articles

    Area of Science:

    • Immunology
    • Molecular Biology
    • Oncology

    Background:

    • Interleukin 2 (IL 2) is a key cytokine regulating immune cell proliferation and function.
    • Defects in IL 2 production or response are observed in various immunodeficiency disorders.
    • IL 2 exhibits significant anti-tumor activity in preclinical models.

    Purpose of the Study:

    • To review the biochemistry and molecular biology of IL 2.
    • To examine the IL 2 receptor and normal T-cell activation.
    • To explore IL 2's role in immunodeficiency, leukemia, and cancer therapy.

    Main Methods:

    • Literature review of IL 2 biochemistry, molecular biology, and receptor data.
    • Analysis of IL 2 production and response in immune disorders.
    • Examination of IL 2's therapeutic potential in cancer models and human trials.

    Related Experiment Videos

    Main Results:

    • IL 2 is central to the activity of B-cells, T-cells, Natural Killer, and Lymphokine Activated Killer cells.
    • Abnormalities in IL 2 are associated with immunodeficiency states and leukemia.
    • IL 2 demonstrates anti-tumor effects and is being investigated for cancer treatment.

    Conclusions:

    • IL 2 is a critical immunomodulator with therapeutic implications.
    • Understanding IL 2 pathways is vital for treating immune defects and cancers.
    • Further research into IL 2 is warranted for its clinical application in oncology.